Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
Rhea-AI Summary
Axogen (NASDAQ: AXGN) will present at the J.P. Morgan 2026 Healthcare Conference. Management is scheduled to present on Thursday, January 15, 2026 at 10:30 AM Pacific Standard Time. A live audio webcast will be available via the company’s investor relations site at ir.axogeninc.com.
This provides investors and analysts an opportunity to hear management commentary on recent developments and strategic priorities directly from company leadership.
Positive
- None.
Negative
- None.
News Market Reaction 19 Alerts
On the day this news was published, AXGN gained 6.95%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $95M to the company's valuation, bringing the market cap to $1.46B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: SIBN up 3.08%, while TNDM, IRMD, OFIX, and AVNS are modestly negative. This points to stock-specific rather than sector-driven trading for AXGN.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | FDA approval | Positive | +2.3% | FDA approved BLA for Avance nerve allograft with accelerated indications. |
| Nov 04 | Investor conferences | Positive | +2.2% | Announced participation in three late-2025 healthcare investor conferences. |
| Oct 29 | Q3 earnings | Positive | +23.1% | Reported strong Q3 revenue growth, margin strength, and raised 2025 guidance. |
| Oct 15 | Earnings date notice | Neutral | +1.6% | Announced timing and access details for the Q3 2025 earnings release. |
| Aug 27 | Investor conferences | Positive | -0.4% | Outlined participation in four September 2025 investor conferences. |
Recent news with clear positive fundamentals (Q3 earnings, FDA BLA approval) has typically seen aligned positive price reactions, while routine conference participation has produced smaller and occasionally mixed moves.
Over the past six months, Axogen reported strong Q3 2025 financial results with double‑digit revenue growth and a return to profitability, and it secured FDA BLA approval for Avance with commercial availability expected in early Q2 2026. The stock reacted positively to these fundamental milestones. Multiple conference participation announcements in August, October, and November 2025 produced modest, mixed price moves, suggesting conferences are a lower‑impact catalyst compared with earnings and regulatory approvals.
Market Pulse Summary
The stock moved +7.0% in the session following this news. A strong positive reaction aligns with Axogen’s recent pattern where substantive milestones, like the Q3 2025 earnings beat and FDA BLA approval for Avance, have attracted buying interest. Participation in the J.P. Morgan Healthcare Conference could be interpreted as increased investor visibility, especially following these catalysts. However, past conference announcements have sometimes produced only modest or mixed moves, so sustainability would depend on follow‑up data, guidance, or incremental disclosures around Avance commercialization.
AI-generated analysis. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference.
Axogen’s management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at ir.axogeninc.com.
About Axogen
Axogen (NASDAQ: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.
For more information, visit www.axogeninc.com.
Contact: Axogen, Inc. InvestorRelations@axogeninc.com
FAQ
When will Axogen (NASDAQ: AXGN) present at the J.P. Morgan 2026 Healthcare Conference?
How can I watch the Axogen (AXGN) presentation on January 15, 2026?
What time is the Axogen (AXGN) presentation in Eastern Time?
Will the Axogen (AXGN) J.P. Morgan presentation include a Q&A with management?
Where on Axogen’s site is the January 15, 2026 webcast posted?
Is the Axogen (AXGN) presentation at J.P. Morgan 2026 open to the public?
